Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 5Venous Thromboembolism 4Venous Thrombosis 3Pulmonary Embolism 3Thrombosis 1Prostatic Neoplasms 1Myeloproliferative Disorders 1Multiple Endocrine Neoplasia Type 1 1Hot Flashes 1Embolism 1Cushing Syndrome 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Non-small Cell Lung Cancer 1

Interventions

relacorilant 6Mifepristone 4Osilodrostat 3Corlux 3Metyrapone 2Adrenalectomy 2pembrolizumab 1Perceived Stress Scale 1Observation 1Dabigatran 1Continuous Glucose Monitoring 1Abiraterone Acetate 1ASP3662 14-amino-4'-hydroxylaminodiphenylsulfone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cushing Syndrome × Dabigatran × Clear all
NCT05347979 2023-02-09

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Corcept Therapeutics

Phase 1 Completed
30 enrolled

Cushing Syndrome, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡